russr

Russia claims it has completed the first human trial for COVID-19 vaccine

pharmafile | July 13, 2020 | News story | Sales and Marketing COVID-19, coronavirus, vaccines 

Russia has become the first country to complete a COVID-19 vaccine trial on humans, according to the Russian News Agency.

Clinical trials were conducted on volunteers at the Sechenov First Moscow State Medical University and involved 38 people in two separate groups. The vaccine proved to be effective and safe. Vadim Tarasov, the Director of the Institute for Translational Medicine and Biotechnology said: “Sechenov University has successfully completed tests on volunteers of the world’s first vaccine against coronavirus.

“Sechenov University in a pandemic situation acted not only as an educational institution but also as a scientific and technological research center that is able to participate in the creation of such important and complex products as drug. We worked with this vaccine, starting with preclinical studies and protocol development.”

The two volunteer groups will be discharged on 15 and 20 July and will remain under medical supervision. Prior to the human trials, the vaccine was tested for its toxicity, safety, immunogenicity and effectiveness in large and small animals at the Russian Defence Ministry’s 48th Central Research Institute.

The vaccine is being developed and produced by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology along with the Russian defence ministry.

Conor Kavanagh

Related Content

FDA approves first oral antiviral to treat adult patients with COVID-19

The US Food and Drug Administration (FDA) has announced that it has approved the oral …

CureVac and GSK begin phase 1 trial for mRNA flu vaccine candidates

CureVac and GSK have announced that the first patient in the phase 1 section of …

moderna_norwood_plant

Moderna and Pfizer COVID-19 vaccine protection declines over time

Data presented by Pfizer and Moderna ahead of the FDA’s vaccine advisory committee meeting on …

Latest content